Drugs /

liposomal doxorubicin

Back to Drugs List

Overview

Generic Name(s):
liposomal doxorubicin
Trade Name(s):
Evacet, Doxil, Doxilen, Lipodox, Dox-Sl, and Caelyx

Clinical Trials

View Clinical Trials for liposomal doxorubicin

Liposomal doxorubicin has been investigated in 10 clinical trials, of which 7 are open and 3 are closed. Of the trials investigating liposomal doxorubicin, 2 are phase 1 (1 open), 1 is phase 1/phase 2 (0 open), 5 are phase 2 (4 open), and 2 are phase 3 (2 open).

ERBB2 Amplification, HER2 Overexpression, and HER2 Positive are the most frequent biomarker inclusion criteria for liposomal doxorubicin clinical trials.

Breast carcinoma, ovarian carcinoma, and central nervous system lymphoma are the most common diseases being investigated in liposomal doxorubicin clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Liposomal Doxorubicin
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Liposomal Doxorubicin
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating liposomal doxorubicin and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
DOXIL, Dox-SL, Evacet, LipoDox, CAELYX, Doxilen

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.